--- canonical_url: https://www.stockexpertai.com/earnings/abbv last_updated: 2026-05-03T20:44:10.591Z --- # AbbVie Inc. (ABBV) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-03T20:44:09.244Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $206.60 (▼ -2.23%) | fmp:quote | | Market Cap | $365.4B | fmp:profile | | 52w range | $176.57 – $244.81 | fmp:quote | | Earnings | Thu 30 Jul | fmp:earnings-history | | EPS estimate | $3.73 (+26% YoY) | fmp:earnings-estimate | | Revenue estimate | $16.8B | fmp:earnings-estimate | | Beat streak | 5/4 | fmp:earnings-history | | Rating | C- (overall 1/5) | fmp:ratings | | Analyst median target | $260 (+25.8% upside) | fmp:price-target-consensus | | MoonshotScore | 56/100 | derived | | Council | 3/6 bullish | derived | | Munger verdict | Undervalued | derived | ## AbbVie Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $16.8B^{[FMP est]}, EPS $3.73^{[FMP est]}. 5 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** C- · **Stance:** BUY · **Council:** 3/6 · **Moonshot:** 56 = MoonshotScore 56^{[9-pillar formula]} + Council 3/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Fy Eps Guidance Increase AbbVie is raising its full year adjusted earnings per share guidance by $0.12 and now expects adjusted EPS between $14.08 and $14.28 due to strong performance. > "Based on this strong performance, we are raising our full year adjusted earnings per share guidance by $0.12 and now expect adjusted EPS between $14.08 and $14.28." > — Robert Michael, Chairman and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 2. Rinvoq Growth Expectations Rinvoq global sales are expected to reach $10.2 billion, reflecting strong performance in the room and gastro indications. > "Rinvoq global sales of $10.2 billion, an increase of $100 million, reflecting strong performance in the room and gastro indications." > — Scott Reents, Executive Vice President and Chief Financial Officer, Expectation / Guide · Q1 FY2026 ### 3. Neuroscience Revenue Growth Total Neuroscience revenues are expected to reach $12.6 billion an increase of $100 million, reflecting momentum across the portfolio. > "Total Neuroscience revenues of $12.6 billion an increase of $100 million, reflecting momentum across the portfolio." > — Scott Reents, Executive Vice President and Chief Financial Officer, Investor Focus · Q1 FY2026 ### 4. Skyrizi Ibd Growth Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year. > "Performance also remains very robust in IBD, where Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year." > — Jeffrey Stewart, Executive Vice President, Chief Commercial Officer, Investor Focus · Q1 FY2026 ### 5. Us Rd Investment As part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, the company recently announced construction of several new manufacturing sites. > "Lastly, as part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, we recently announced construction of several new manufacturing sites." > — Robert Michael, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-2.7%, contraction) | | Gross Margin | 8.0 | strong | Q1: very high margin (83.5%, software/cloud territory) | | Operating Leverage | 3.0 | weak | op margin very strong (31.6%, scale leverage) | | Cash Runway | 10.0 | strong | FCF very strong ($4.9B, 14.9× CapEx) | | R&D Intensity | 7.0 | strong | balanced R&D investment (11.2%) | | Price Momentum | 4.0 | medium | RSI 48.9 balanced, 50d below | | News Sentiment | 7.0 | strong | strong buy consensus (73%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +25.8% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 49 | | Klarman | bull | value · target upside +25.8% | | Buffett | neutral | quality · ROE score 1/5 | | Munger | bull | valuation · target upside +25.8% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Undervalued - **Financial Health:** Weak - **Margin of Safety:** Strong - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 48.9 — dengeli — yön sinyali zayıf - **50d MA:** $215 — hisse %3.7 altında — kısa vadeli direnç - **200d MA:** $218 — hisse %5.2 altında — uzun vadeli baskı - **Volume (10d):** -18% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $2.97 | $2.88 | BEAT | +3.3% | | Q3 FY25 | $1.86 | $1.77 | BEAT | -2.8% | | Q4 FY25 | $2.71 | $2.65 | BEAT | +0.9% | | Q1 FY26 | $2.65 | $2.59 | +2.3% EPS | +3.6% | Q1 (April 29, 2026): EPS $2.65 vs $2.59 est^[FMP], +2.3% beat. D+1 movement: +3.6%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $3.73 + CapEx discipline** Threshold: EPS > $3.73^{[FMP est]}. Target: Break above median target $260^{[FMP target]}; high target $294^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $3.73 + CapEx < $329.0M** Threshold: EPS ≈ $3.73^{[FMP est]}, Q4 CapEx < $329.0M^[FMP]. Target: Consolidation in the band between current $207^[FMP] and median $260^[FMP]. ### Scenario C · Miss **EPS < $3.62 or CapEx ≥ $329.0M** Threshold: EPS < $3.62^{[FMP est×0.97]}. Target: Current $207 below SMA200 $218^[FMP], if rejection continues, $185^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.65 vs $2.59 beat^[FMP], stock +3.6% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $329.0M^{[FMP cashflow]}. Q1 op margin 31.6%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $260 (+25.8% upside vs current $207) - **High / Low:** $294 / $223 - **Buy / Hold / Sell:** 24 / 9 / 0 - **Analyst count:** 10 (last quarter), 75 all-time ## Additional Transcript Insights ### 1. skyrizi_psoriatic_leadership **Claim:** Skyrizi maintains its leadership in the psoriatic disease market, holding a significant market share over all biologics and oral treatments. **Evidence (transcript):** "We continue to demonstrate exceptional performance across psoriatic disease, where we are gaining share and have clear leadership over all biologics and orals by a very wide margin." **Numbers:** — ### 2. skyrizi_ibd_growth **Claim:** Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year. **Evidence (transcript):** "Performance also remains very robust in IBD, where Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year." **Numbers:** 30% ### 3. rinvoq_growth_expectations **Claim:** Rinvoq global sales are expected to reach $10.2 billion, reflecting strong performance in the room and gastro indications. **Evidence (transcript):** "Rinvoq global sales of $10.2 billion, an increase of $100 million, reflecting strong performance in the room and gastro indications." **Numbers:** $10.2 billion, $100 million ### 4. neuroscience_revenue_growth **Claim:** Total Neuroscience revenues are expected to reach $12.6 billion an increase of $100 million, reflecting momentum across the portfolio. **Evidence (transcript):** "Total Neuroscience revenues of $12.6 billion an increase of $100 million, reflecting momentum across the portfolio." **Numbers:** $12.6 billion, $100 million ### 5. fy_eps_guidance_increase **Claim:** AbbVie is raising its full year adjusted earnings per share guidance by $0.12 and now expects adjusted EPS between $14.08 and $14.28 due to strong performance. **Evidence (transcript):** "Based on this strong performance, we are raising our full year adjusted earnings per share guidance by $0.12 and now expect adjusted EPS between $14.08 and $14.28." **Numbers:** $0.12, $14.08, $14.28 ### 6. us_rd_investment **Claim:** As part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, the company recently announced construction of several new manufacturing sites. **Evidence (transcript):** "Lastly, as part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, we recently announced construction of several new manufacturing sites." **Numbers:** $100 billion --- *Data source: FMP (live query, 2026-05-03), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*